#### Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 3

#### ELITE PHARMACEUTICALS INC /DE/

Form 3 June 12, 2009

# FORM 3

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, response...

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

I. Name and A Person <u>*</u> EPIC INV			2. Date of Event Requiring Statement (Month/Day/Year)	3. Issuer Name and Ticker or Trading Symbol ELITE PHARMACEUTICALS INC /DE/ [ELI]					
(Last)	(First)	(Middle)	06/03/2009	4. Relationship of Reporting Person(s) to Issuer (Check all applicable)			5. If Amendment, Date Original Filed(Month/Day/Year)		
227-15 NOR AVENUE	RTH CON	DUIT							
(Street)				Director Officer (give title below	Othe	r	Filing(Check Applicable Line) _X_ Form filed by One Reporting		
LAURELTO	ON, NY	11413					Person Form filed by More than One Reporting Person		
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Beneficially Owned						
1.Title of Secur (Instr. 4)	rity		2. Amount o Beneficially (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nat Owne (Instr.	*		
Reminder: Repo			ach class of securities benefic	ially S	EC 1473 (7-02	2)			
	infor requi	mation cont ired to respo	spond to the collection of ained in this form are not and unless the form displed MB control number.	t					

#### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Date Exerc	2. Date Exercisable and		3. Title and Amount of		5.	6. Nature of	
Security	Expiration Date		Securities Underlying		Conversion	Ownership	Indirect Beneficial	
(Instr. 4)	Instr. 4) (Month/Day/Year)		*		or Exercise Price of	Form of	Ownership	
						Derivative	(Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I)		

#### Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 3

(Instr. 5)

Series E Convertible Preferred Stock	06/03/2009	(3)	Common Stock	20,000,000	\$ 0.2 (1)	D	Â
Warrants	06/03/2009	06/03/2016	Common Stock	40,000,000	\$ 0.0625	D	Â

## **Reporting Owners**

Reporting Owner Name / Address

Director 10% Owner Officer Other

EPIC INVESTMENTS, LLC

227-15 NORTH CONDUIT AVENUE Â Â X Â

LAURELTON, NYÂ 11413

Date

# **Signatures**

/s/ Ram Potti, Vice President 06/05/2009

\*\*Signature of Reporting
Person

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Epic Investments, LLC, a Delaware limited liability company ("EI") owns 1,000 shares of Elite Pharmaceuticals, Inc.'s ("Elite") Series E
- (1) Convertible Preferred Stock, each having a price of \$1,000 per share and convertible, at a conversion price of \$0.05 per share, into 20,000 shares of Elite's Common Stock.
- (2) EI owns warrants to purchase up to an aggregate of 40,000,000 shares of Elite's Common Stock excerisable at \$0.0625 per share.
- (3) Not Applicable

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2